GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Cyclically Adjusted PS Ratio

Aurinia Pharmaceuticals (FRA:IKAP) Cyclically Adjusted PS Ratio : 10.51 (As of May. 14, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-05-14), Aurinia Pharmaceuticals's current share price is €4.519. Aurinia Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.43. Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 10.51.

The historical rank and industry rank for Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:IKAP' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.79   Med: 8.41   Max: 84.82
Current: 10.54

During the past years, Aurinia Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 84.82. The lowest was 0.79. And the median was 8.41.

FRA:IKAP's Cyclically Adjusted PS Ratio is ranked worse than
69.79% of 513 companies
in the Biotechnology industry
Industry Median: 5.53 vs FRA:IKAP: 10.54

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Aurinia Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.321. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.43 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Aurinia Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 35.28 55.15 16.04 20.97

Aurinia Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.24 28.27 19.67 20.97 10.52

Competitive Comparison of Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Aurinia Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=4.519/0.43
=10.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Aurinia Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.321/125.4675*125.4675
=0.321

Current CPI (Mar. 2024) = 125.4675.

Aurinia Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.002 99.473 0.003
201409 0.002 99.394 0.003
201412 0.002 98.367 0.003
201503 0.002 99.789 0.003
201506 0.002 100.500 0.002
201509 0.002 100.421 0.002
201512 0.002 99.947 0.003
201603 0.002 101.054 0.002
201606 0.002 102.002 0.002
201609 0.001 101.765 0.001
201612 0.001 101.449 0.001
201703 0.000 102.634 0.000
201706 0.004 103.029 0.005
201709 0.000 103.345 0.000
201712 0.000 103.345 0.000
201803 0.000 105.004 0.000
201806 0.000 105.557 0.000
201809 0.004 105.636 0.005
201812 0.000 105.399 0.000
201903 0.000 106.979 0.000
201906 0.000 107.690 0.000
201909 0.002 107.611 0.002
201912 0.000 107.769 0.000
202003 0.000 107.927 0.000
202006 0.000 108.401 0.000
202009 0.000 108.164 0.000
202012 0.325 108.559 0.376
202103 0.006 110.298 0.007
202106 0.043 111.720 0.048
202109 0.097 112.905 0.108
202112 0.155 113.774 0.171
202203 0.139 117.646 0.148
202206 0.188 120.806 0.195
202209 0.397 120.648 0.413
202212 0.189 120.964 0.196
202303 0.225 122.702 0.230
202306 0.268 124.203 0.271
202309 0.358 125.230 0.359
202312 0.288 125.468 0.288
202403 0.321 125.468 0.321

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aurinia Pharmaceuticals  (FRA:IKAP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Aurinia Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurinia Pharmaceuticals (FRA:IKAP) Business Description

Traded in Other Exchanges
Address
4464 Markham Street, Suite 1203, Victoria, BC, CAN, V8Z 7X8
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

Aurinia Pharmaceuticals (FRA:IKAP) Headlines

No Headlines